Independent directory Public ClinicalTrials.gov records United States
Sponsor Directory

Eli Lilly and Company clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1967
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Eli Lilly and Company
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Eli Lilly and Company. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 121–132 of 1,967 matching trials for sponsor Eli Lilly and Company.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Conditions
Mantle Cell Lymphoma
Interventions
Pirtobrutinib, Rituximab, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Conditions
Frontal Fibrosing Alopecia
Interventions
Baricitinib 4 MG Oral Tablet
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus
Interventions
Baricitinib 4 milligram Oral Tablet
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Active, not recruiting Phase 2 Interventional Results available

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

NCT03994796
Conditions
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
435
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more
Conditions
Alzheimer Disease
Interventions
LY3954068, Placebo, Flortaucipir F18
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Maitland, Florida • The Villages, Florida • Decatur, Georgia + 3 more
Conditions
Pouchitis, Pouches, Ileoanal, Pouch, Ileal
Interventions
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
Enrolling by invitation Phase 4 Interventional

INSIGHT-IBD Pragmatic Study

NCT07686757
Conditions
Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions
Mirikizumab, Anti-TNF agents, anti-integrin antibodies, IL-12, IL-23
Drug
Lead sponsor
Specialty Networks Research.
Network
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Sun City, Arizona • Tucson, Arizona • Glenview, Illinois + 10 more
Conditions
Alzheimer Disease, Dementia, Plaque, Amyloid
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
55
States / cities
Phoenix, Arizona • Huntington Beach, California • Irvine, California + 48 more
Conditions
Perennial Allergic Rhinitis (PAR)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more
Conditions
Triple Negative Breast Cancer
Interventions
Drug 1: LY3023414; Drug 2: Prexasertib
Combination Product
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Atopic Dermatitis, Eczema
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 18 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
Conditions
Bladder Cancer
Interventions
Abemaciclib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
New York, New York • Dallas, Texas

About this Eli Lilly and Company sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Eli Lilly and Company is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Eli Lilly and Company trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Eli Lilly and Company.